DOCSLIB.ORG

Life Sciences and Healthcare

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Life Sciences and Healthcare Life Sciences and Healthcare Beijing Guangzhou Hong Kong Shanghai Shenzhen 27/F, North Tower 17/F, International Finance 26/F, One Exchange Square 24/F, HKRI Centre Two, 17/F, Tower One, Kerry Plaza Beijing Kerry Centre Place, 8 Huaxia Road, 8 Connaught Place, Central HKRI Taikoo Hui 1 Zhong Xin Si Road 1 Guanghua Road Zhujiang New Town Hong Kong 288 Shi Men Yi Road Futian District Chaoyang District Guangzhou 510623, China Shanghai 200041, China Shenzhen 518048, China Beijing 100020, China Tel: +86 10 5769 5600 Tel: +86 20 3225 3888 Tel: +852 3976 8888 Tel: +86 21 2208 1166 Tel: +86 755 8159 3999 Fax:+86 10 5769 5788 Fax:+86 20 3225 3899 Fax:+852 2110 4285 Fax:+86 21 5298 5599 Fax:+86 755 8159 3900 www.fangdalaw.com Life Sciences and Healthcare Life Sciences and Healthcare 01 The Preeminent China-based International Law Firm Founded in 1993 and one of the most prestigious law firms Our service to clients is premised on the dual foundations in the region, Fangda Partners has over 700 lawyers. We of strong local law capabilities and a global business outlook. serve a wide variety of major clients – including large MNCs, Our lawyers are qualified in many jurisdictions, including global financial institutions, leading Chinese enterprises the People's Republic of China, Hong Kong SAR, England and fast-growing Hi-tech companies – on an extensive range and Wales, the United States, Singapore and Australia. of commercial matters through our network offices in Beijing, Guangzhou, Hong Kong, Shanghai and Shenzhen, Our understanding of the laws and processes in major offering PRC law and Hong Kong law. jurisdictions around the world enables us to advise our clients effectively on the largest and most complicated We are the firm of choice for clients’ most challenging cross-border matters in China and elsewhere. Our strengths transactions and legal issues in many practice areas. Since have been widely recognized by our clients and peers. we were founded, we have advised on some of the largest Chambers has commented on our cross-border capabilities and most complex corporate and finance transactions in in the following terms – “outstanding quality of its lawyers”, China, the region and globally. We have also assisted our “high level of service that is comparable to international clients with many renowned and complex cases and firms”, and “strong global outlook”. arbitrations, compliance and government investigations in the region. Top Tier Firm: China Competition: China Firm of the Year IFLR 1000 2020 China Law and Practice 2018 China Firm of the Year Investment Funds: China Firm of the Year Respected team with a strong track record in a variety of healthcare-related transactions China Law and Practice 2019 China Law and Practice 2018 and contentious issues. Well-known, full-service firm advising both international and local clients on the healthcare industry. Clients include high-profile pharmaceutical and biotech PRC Firm, Hong Kong Office of the Year Corporate Firm of the Year companies, private equity firms and private medical institutions. Asian Legal Business 2018 IFLR Asia Awards 2018 M&A: China Firm of the Year Corporate Investigations/Anti-Corruption China Law and Practice 2019 (PRC Firms): Band 1 Chambers Asia Pacific 2020 —— Chambers Asia Pacific 2020 Life Sciences and Healthcare Life Sciences and Healthcare 01 The Preeminent China-based International Law Firm Founded in 1993 and one of the most prestigious law firms Our service to clients is premised on the dual foundations in the region, Fangda Partners has over 700 lawyers. We of strong local law capabilities and a global business outlook. serve a wide variety of major clients – including large MNCs, Our lawyers are qualified in many jurisdictions, including global financial institutions, leading Chinese enterprises the People's Republic of China, Hong Kong SAR, England and fast-growing Hi-tech companies – on an extensive range and Wales, the United States, Singapore and Australia. of commercial matters through our network offices in Beijing, Guangzhou, Hong Kong, Shanghai and Shenzhen, Our understanding of the laws and processes in major offering PRC law and Hong Kong law. jurisdictions around the world enables us to advise our clients effectively on the largest and most complicated We are the firm of choice for clients’ most challenging cross-border matters in China and elsewhere. Our strengths transactions and legal issues in many practice areas. Since have been widely recognized by our clients and peers. we were founded, we have advised on some of the largest Chambers has commented on our cross-border capabilities and most complex corporate and finance transactions in in the following terms – “outstanding quality of its lawyers”, China, the region and globally. We have also assisted our “high level of service that is comparable to international clients with many renowned and complex cases and firms”, and “strong global outlook”. arbitrations, compliance and government investigations in the region. Top Tier Firm: China Competition: China Firm of the Year IFLR 1000 2020 China Law and Practice 2018 China Firm of the Year Investment Funds: China Firm of the Year Respected team with a strong track record in a variety of healthcare-related transactions China Law and Practice 2019 China Law and Practice 2018 and contentious issues. Well-known, full-service firm advising both international and local clients on the healthcare industry. Clients include high-profile pharmaceutical and biotech PRC Firm, Hong Kong Office of the Year Corporate Firm of the Year companies, private equity firms and private medical institutions. Asian Legal Business 2018 IFLR Asia Awards 2018 M&A: China Firm of the Year Corporate Investigations/Anti-Corruption China Law and Practice 2019 (PRC Firms): Band 1 Chambers Asia Pacific 2020 —— Chambers Asia Pacific 2020 Life Sciences and Healthcare Life Sciences and Healthcare 02 03 Our Life Sciences and Diversified clientele One legal solution across multiple practices Our clients range from large and medium-sized multinational We are set up in such a way to offer clients a seamless service Healthcare Practice pharmaceutical companies, research-based pharmaceutical across offices and practice areas. We provide integrated companies, medical device companies, distributors, contract teams drawn from different legal disciplines to cover every sales organizations, contract research organizations, and angle of a deal. We recognize the importance of identifying Focused service team industry associations to private equity funds and venture early the key legal issues and planning a strategy to ensure capital businesses. We advise companies headquartered the most effective management of any transaction on We are one of the few law firms in China that has a dedicated team in the in the U.S., Europe, China and across Asia. which we are retained. One team, one solution is our practiced pharmaceutical, biotechnology and healthcare sector. We provide the full method of working. range of commercial legal services to pharma, biotechnology and healthcare Our lawyers have deep knowledge of the sector, enabling businesses. Some of our team members have worked for leading pharmaceutical us to advise on the full range of legal issues that arise from and medical device companies and regulatory authorities. We combine our clients’ businesses. This includes in-depth understanding Working relationship with authorities legal expertise with keen commercial understanding to enable our clients of research and development, clinical trials, manufacturing / to achieve their business objectives with the minimum of fuss. contract manufacturing promotion, and distribution / We engage constructively with the Chinese agencies that retail/logistics of pharmaceutical products and medical govern the activities of companies in the life sciences and devices, as well as the establishment, operation and management healthcare sector. We have regulator interactions with NMPA, Extensive range of experience of hospitals, personal clinics and innovative healthcare SAMR (formerly SAIC) and their local counterparts. Our service platforms. antitrust and regulatory compliance team also has a long Our life sciences and healthcare practice provides a wide range of services. history of dealing with SAMR, NDRC, MOFCOM and other Our past experience in the industry covers mergers and acquisitions, regulatory authorities. product-driven transactions, foreign direct investment, investments by private equity funds and venture capital, domestic and overseas capital markets, compliance, in-license and out-license, commercial bribery, data protection, vertical and horizontal monopoly arrangements, IP enforcement Compliance/ and regulatory advice. We have specialist expertise in advising on complicated Commercial Bribery commercial transactions with a high degree of regulatory impact (such IP Protection as those involving drugs and medical devices), where extensive industry knowledge and a combination of expertise in different disciplines is required, Capital Markets in addition to routine deal execution skills. M&A / Reorganization Distribution R&D Model Pricing/Competition Medical Services Regulatory/Permit Product License Leveraging the firm's wider expertise, the team is well experienced in handling IP, M&A, capital markets and regulatory compliance as well as government enforcement matters. Houses specialists with diverse backgrounds, with previous work experience such as doctors and in-house counsel. Healthcare and Life Sciences (PRC Firms): Tier 1 —— Chambers
Load more

Recommended publications
  • Corporate Venturing Report 2019
    Corporate Venturing 2019 Report SUMMIT@RSM All Rights Reserved. Copyright © 2019. Created by Joshua Eckblad, Academic Researcher at TiSEM in The Netherlands. 2 TABLE OF CONTENTS LEAD AUTHORS 03 Forewords Joshua G. Eckblad 06 All Investors In External Startups [email protected] 21 Corporate VC Investors https://www.corporateventuringresearch.org/ 38 Accelerator Investors CentER PhD Candidate, Department of Management 43 2018 Global Startup Fundraising Survey (Our Results) Tilburg School of Economics and Management (TiSEM) Tilburg University, The Netherlands 56 2019 Global Startup Fundraising Survey (Please Distribute) Dr. Tobias Gutmann [email protected] https://www.corporateventuringresearch.org/ LEGAL DISCLAIMER Post-Doctoral Researcher Dr. Ing. h.c. F. Porsche AG Chair of Strategic Management and Digital Entrepreneurship The information contained herein is for the prospects of specific companies. While HHL Leipzig Graduate School of Management, Germany general guidance on matters of interest, and every attempt has been made to ensure that intended for the personal use of the reader the information contained in this report has only. The analyses and conclusions are been obtained and arranged with due care, Christian Lindener based on publicly available information, Wayra is not responsible for any Pitchbook, CBInsights and information inaccuracies, errors or omissions contained [email protected] provided in the course of recent surveys in or relating to, this information. No Managing Director with a sample of startups and corporate information herein may be replicated Wayra Germany firms. without prior consent by Wayra. Wayra Germany GmbH (“Wayra”) accepts no Wayra Germany GmbH liability for any actions taken as response Kaufingerstraße 15 hereto.
    [Show full text]
  • History, Development and Corporate Structure
    This document is in draft form, incomplete and subject to change and that the information must be read in conjunction with the section headed “Warning” on the cover of this document. HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE OVERVIEW We are a medtech company dedicated to the research, development and commercialization of innovative medical devices in the field of structural heart diseases with an established leadership position in the transcatheter mitral valve (TMV) market in China. For further details, please refer to the section headed “Business” in this document. The Company was established in the PRC as a limited liability company on December 22, 2016 by Mr. Dai, being an executive Director, and Ms. Yang, being an executive Director. For the biographical details of Mr. Dai and Ms. Yang, please refer to the section headed “Directors, Supervisors and Senior Management” in this document. After a series of share transfers and capital injections, the Company was converted into a joint stock company with limited liability and renamed as “Shanghai Hanyu Medical Technology Co., Ltd. (上海捍宇醫療科技股份有限 公司)”. In March 2021, the registered capital of the Company was increased and there has been no change of share capital since then. MILESTONES OF DEVELOPMENT The following table sets forth the key milestones of our development: Year Key Milestones and Achievements December 2016 We were established as a limited liability company in the PRC under the name of “Shanghai Hanyu Medical Technology Corporation Limited (上海捍宇醫療科技有限公司)”. April 2017 We obtained an exclusive license and purchase option regarding the ValveClamp Patent. July 2018 We launched an exploratory first-in-human (FIM) clinical trial for ValveClamp.
    [Show full text]
  • Venture Capital Report
    Venture Capital Report China | 1 Q | 2018 VENTURE CAPITAL REPORT VENTURE CAPITAL REPORT The following report presents Dow Jones VentureSource’s quarterly findings for Chinese venture capital fundraising, investment, valuation, and liquidity. The included charts and graphs offer a comprehensive view of the trends currently affecting the venture capital market. Highlights for 1Q 2018 include: • China venture capital fundraising increased in both amount raised and the number of funds; • Amount flowed into venture backed Chinese companies increased, although the deal number dropped; • Amount raised through mergers and acquisitions (M&As) declined; while capital raised via initial public offerings (IPOs) climbed. VENTURE CAPITAL REPORT 2 GROWTH EQUITY Starting this quarter, we are reporting on Growth Equity. VentureSource has always tracked this space, but until now they were excluded from the quarterly statistics. Please note that Growth deals will be included in the Later Stage category, a subsection of Venture Capital Investment. We define Growth Equity as a minority stake investment in privately owned, mature companies that meet the following criteria: • No prior equity investment within the first 3 years of business operations; and • A proven business model -- generating revenue or profitable; and • No VC-type round series is used by the company to label the transaction; and • At least one institutional investor participated in the deal. We recently reviewed our entire database to ensure that all companies and transactions are classified consistent with the above criteria. As a result of this review, we re-characterized thousands of historical deals from VC to Growth, or from Growth to VC. As with our Venture Capital statistics, we exclude companies formed for the sole purpose of acquiring other companies, properties, natural resources, or interests.
    [Show full text]
  • 2016 China Leading Fintech 50
    2016 China Leading Fintech 50 KPMG China September 2016 Fintech 50 KPMG Survey Page WeChat 1 Page Number 01 Disruption & breakthrough 4 02 Overview 6 03 The 50 16 04 Appendix 67 Appendix I List of institutional investors 68 Appendix II Global comparison 69 Appendix III Regulatory update 70 Appendix IV KPMG China Fintech experts 74 Appendix V Glossary of abbreviated terms 75 About KPMG 76 Contact us 77 Disclaimer: The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavour to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. © 2016 KPMG Advisory (China) Limited , a member of the KPMG network of independent member firms affiliated with 2 KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved. Printed in China. 01 Disruption & breakthrough © 2016 KPMG Advisory (China) Limited , a member of the KPMG network of independent member firms affiliated with 3 KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved. Printed in China. Disruptive changes and breakthroughs Comprehensive service scenarios Credit Products Consumer cards lending Intelligence Payment Housing/car Data loans Precision Risk marketingIndividuals pricing Insurance Personal Anti-fraud finance Transactions Wealth management Quantitative Financial Portfolio trading markets management Payment Products and Bills receipts Intelligence Risk Data Risk control pricing Enterprises Wealth (small and Credit loans management medium-sized) (supply/industrial chain) Anti-fraud Leasing Pledged loans The picture above listed in no particular order，it is only a schematic diagram sorted by public information.
    [Show full text]
  • Venture Capital Report
    Venture Capital Report China | 4Q | 2014 Venture Capital Report The following report presents Dow Jones VentureSource’s quarterly findings for Chinese venture capital fundraising, investment, valuation, and liquidity. The included charts and graphs offer a comprehensive view of the trends currently affecting the venture capital market. Highlights for 4Q 2014 include: Chinese venture capital fundraising fails to improve on previous quarter, however, total fundraising for year more than doubles that of 2013; Venture capital investment into Chinese companies more than doubles 3Q 2014 total; Overall exit activity improves from 3Q 2014 despite fall in mergers and acquisitions (M&As) as Initial public offerings (IPOs) rally in both number of offerings and dollars raised. 2 Venture Capital Report Chinese Venture Capital Fundraising Fails to Improve in 4Q 2014 Chinese venture fundraising declined to $339 million across 9 funds during 4Q 2014. The quarter represents FUNDRAISING the lowest fundraising accumulation since 2Q 2013 when six funds raised just $140 million. In comparison with the same period last year, dollars raised fell by 57% while the number of venture funds completing closings declined by 25%. Le Fund’s II fund and Arbor Ventures’ fund I were the joint largest of 4Q 2014, raising $100 million apiece, accounting for 59% of the total amount for the quarter combined. Looking at the year as a whole, however, 2014 has surpassed the previous year both in terms of dollars raised and the number of completed closings, improving by 131% and
    [Show full text]
  • Cellular Biomedicine Group, Inc
    SECURITIES & EXCHANGE COMMISSION EDGAR FILING Cellular Biomedicine Group, Inc. Form: SC 13E3/A Date Filed: 2021-02-19 Corporate Issuer CIK: 1378624 © Copyright 2021, Issuer Direct Corporation. All Right Reserved. Distribution of this document is strictly prohibited, subject to the terms of use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13E-3 RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) CELLULAR BIOMEDICINE GROUP, INC. (Name of the Issuer) Cellular Biomedicine Group, Inc. CBMG Holdings CBMG Merger Sub Inc. Yunfeng Fund III, L.P. Yunfeng Investment III, Ltd. Yunfeng Capital Limited TF Capital Ranok Ltd. TF Capital Fund III L.P. Winsor Capital Limited TF I Ltd. Tony (Bizuo) Liu Yihong Yao Li (Helen) Zhang Chengxiang (Chase) Dai Dangdai International Group Co., Limited Mission Right Limited Wealth Map Holdings Limited Earls Mill Limited Sailing Capital Overseas Investments Fund, L.P. Sailing Capital Overseas Investments GP, Ltd OPEA SRL Maplebrook Limited Full Moon Resources Limited Viktor Pan Zheng Zhou Novartis AG Novartis Pharma AG (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 15117P102 (CUSIP Number of Class of Securities) Andrew Chan Xin Huang Cellular Biomedicine Group, Inc. CBMG Holdings 209 Perry Parkway, Suite 13 Room 3501, 35th floor, K. Wah Centre, No. 1010, Gaithersburg, Maryland 20877 Middle Huaihai Rd. (301) 825-5320 Shanghai 200031, China +852 2516 6363 With copies to: William Fong, Esq. Morton A. Pierce, Esq. Nima Amini, Esq. White & Case LLP Chang-Do Gong, Esq.
    [Show full text]
  • Table of Contents FORM 20-F Alibaba Group Holding Limited
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report…………… For the transition period from to Commission file number 001-36614 Alibaba Group Holding Limited (Exact name of Registrant as specified in its charter) Cayman Islands (Jurisdiction of incorporation or organization) 26/F Tower One, Times Square 1 Matheson Street, Causeway Bay Hong Kong (Address of principal executive offices) Timothy A. Steinert, Esq., Company Secretary Telephone: +852-2215-5100 Facsimile: +852-2215-5200 Alibaba Group Holding Limited 26/F Tower One, Times Square 1 Matheson Street, Causeway Bay Hong Kong (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, par value US$0.000003125 per share 9988 The Stock Exchange of Hong Kong Limited American Depositary Shares, each representing BABA New York Stock Exchange eight Ordinary Shares Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 21,491,994,944 Ordinary Shares Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Re-Election of Directors of the Fifth Session Of
    12652 \ (Shenzhen Hepalink) \ 05/08/2020 \ M08 THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt about any of the contents of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser. If you have sold or transferred all your Shares in Shenzhen Hepalink Pharmaceutical Group Co., Ltd., you should at once hand this circular together with the proxy form to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular. SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. (深圳市海普瑞藥業集團股份有限公司) (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 9989) RE-ELECTION OF DIRECTORS OF THE FIFTH SESSION OF THE BOARD RE-ELECTION OF SUPERVISORS OF THE FIFTH SESSION OF THE SUPERVISORY COMMITTEE REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF THE FIFTH SESSION OF THE BOARD CREDIT LINE APPLICATION AND PROVISION OF GUARANTEE AMENDMENT OF THE ARTICLES OF ASSOCIATION AND NOTICE OF THE 2020 THIRD EXTRAORDINARY GENERAL MEETING A letter from the Board is set out on pages 3 to 10 of this circular.
    [Show full text]
  • Issue 15, October 2017
    │ Editor's Note Welcome to the 15th issue of the EMEA Private Equity Market Snapshot, a quarterly publication focusing on the private equity [PE] market in Europe, the Middle East & Africa [EMEA] from S&P Global Market Intelligence. This issue opens with a look at EMEA's position in the global private equity landscape as the region continues to ride a favourable trend as a destination for new investments -highlighted by a particularly strong performance from the UK, who accounted for 31% of the region's investments in 2017. We then explore EMEA GPs who, from the start of July to the end of August, have deployed 87% more capital compared to the same period in 2016. They underscored this feat by signing the largest single deal since 2015 -United Capital Partners and others' acquisition of Essar Oil Ltd for €11.4bn. Looking at sub-regional preference globally, like their peers, EMEA PE firms were most interested in investing in the UK. The Information Technology sector has increasingly attracted attention from global PE firms over the last decade. The total capital deployed into IT targets grew by 63%, from €72.6bn in 2007 to €119.3bn during the study period. APAC-based targets have drawn greater interest from global GPs with China continuing to feature more prominently since 2012 (having also featured twice in the top five deals globally in 2016). Finally, we turn our attention to institutional investors, who are continuing to add value to the private equity sector. EMEA was the only region in 2016 with decreasing PE allocations -investors tightened their spend in the region due to economic, social and political uncertainties.
    [Show full text]
  • CHUCK SUN Partner Fangda Partners +86 21 2208 1024 [email protected] PRACTICE AREAS MR
    CHUCK SUN Partner Fangda Partners +86 21 2208 1024 [email protected] PRACTICE AREAS MR. SUN SPECIALIZES IN M&A, PRIVATE EQUITY, VENTURE CAPITAL, OUTBOUND INVESTMENT AND FOREIGN DIRECT INVESTMENT. REPRESENTATIVE MATTERS AND CASES Private Equity and Venture Capital: Represented Yunfeng Capital in: its more than USD $700 million investment (together with Alibaba Group) in NetEase Cloud Music; its more than RMB 2.4 billion investment in Meinian Onehealth Healthcare (SZSE: 002044); and its investment in YITU Technology, AliSports and the TMT sector Represented a buyer consortium led by Standard Chartered Private Equity in: its leveraged buyout of Siyanli, a nationwide high-end beauty franchise business, for more than USD $200 million; its trade sale of majority interests in Siyanli to a group of private equity investors and minority interests in Siyanli to CHJ Jewelry, an A-share listed company, in a share swap (aborted); and its trade sale to MBK Partners Represented a buyer consortium led by China Life Healthcare Fund and SDIC Fund Management Company Ltd. in a more than RMB 3.3 billion Series A financing of Shanghai United Imaging Healthcare Co., Ltd., an advanced medical equipment developer and manufacturer and an innovative medical solutions provider Represented Hillhouse Capital in its investment in Just Biotherapeutics (merged into Transcenta Holding, a global biotherapeutics company) and other biopharmaceutical companies Represented Boyu Capital and 58.com in their investments in Vanke Property Service, the property management
    [Show full text]
  • EXHIBIT L L-1 Possible Timeline for Infusion of Funds by Sequoia Into VIPKID Kobe Bryant Invests in CKGSB Alumna’S Company VIPKID - CKGSB 2/11/21, 5:18 PM
    EXHIBIT L L-1 Possible timeline for infusion of funds by Sequoia into VIPKID Kobe Bryant Invests in CKGSB Alumna’s Company VIPKID - CKGSB 2/11/21, 5:18 PM local and global experience prepared her well to start her own business, VIPKID, which Mi founded in 2013. She later joined CKGSB’s Chuang Community, a start-up incubator that was founded in 2015 by CKGSB Associate Dean Liu Jing together with five well-known CKGSB alumni. VIPKID’s Financing Milestones: Angel round: December 2013, 3 million RMB, from Innovation Works; A round: October 2014, 5 million USD, from MatrixPartners China, followed by Innovation Works and Sequoia Capital. B round: October 2015, 20 million USD, from Northern Light Venture Capital, MatrixPartners China, Sequoia Capital and Innovation Works. C round: August 2016, $100 million, from Sequoia Capital and Jack Ma’s Yunfeng Capital. About VIPKID: Founded in 2013, VIPKID’s mission is to provide the North American elementary school experience to Chinese children – all from the comfort of their home. The company’s sophisticated virtual classroom streams native English-speaking teachers into Chinese homes, linking the world through education. CEO Cindy Mi (left) along with her VIPKID co-founders https://english.ckgsb.edu.cn/new/kobe-bryant-invests-in-ckgsb-alumnas-company-vipkid-2/ Page 4 of 5 L-2: Sequoia describes its “ethos” on its website People Build Companies Sequoia, 1972 and beyond The creative spirits. The underdogs. The resolute. The determined. The outsiders. The defiant. The independent thinkers. The fighters and the true believers. These are the founders with whom we partner.
    [Show full text]
  • Oceanwide Holdings Co Ltd Real Estate 9M18 Credit Report 2 April 2019 China
    Oceanwide Holdings Co Ltd Real Estate 9M18 Credit report 2 April 2019 China OCEANWIDE HOLDINGS CAPITAL STRUCTURE SUMMARY (CNYm) Amount Pro Forma Est Annual Leverage Pro Forma Instrument Issuance date Coupon Maturity Outstanding amount Interest on as of amount as at 30 Sep 18(1) (USD m) Pro Forma amounts 30 Sep 18 Repurchase agreement (repo) < 1 year 7,778 7,778 1,131 Asset-backed securities Nov-17 to Nov-18 0-8.5% Oct-18 to Nov-36 3,022 5,669 824 Total secured debt 10,800 13,447 1,955 2.5x Revenue-linked securities Jul-17 to Jun-18 2.5-6.15% Jun-18 to Jun-21 3,365 3,365 489 Short term bank and other loans (unclassified) < 1 year 50,281 50,281 7,308 Long term bank and other loans (unclassified) < 1 year 41,108 41,108 5,975 Onshore bonds and notes Oct-15 to Sep-18 4.2-9% Jan-19 to Aug-23 26,070 19,678 2,860 Offshore bonds and notes Mar-16 to Dec-18 6-12% Nov-18 to Dec-23 8,883 8,639 1,256 Total debt 140,506 136,518 19,843 32.3x Total debt, adjusted with the Sunac deal NA 108,598 15,785 Cash & cash equivalent(2) 21,883 16,594 2,412 External guarantee 10,593 10,593 Uncommitted credit facilities(3) 11,274 15,000 Net Debt 118,624 119,924 17,431 27.3x Market capitalization CNY 7.48 per share 38,868 Enterprise value 158,792 LTM Adj.
    [Show full text]